Good evening, and welcome to this Q2 investor update with 2cureX. With us today, we have the management team of 2cureX. First, there will be a presentation, and afterwards, a Q&A, where the management team will answer all questions submitted via stockio. We have already received some questions on stockio, and the Q&A is still open so that you can submit questions live as well. I will now hand over the mic to 2cureX for the presentation. Your line is now open. Yes, thank you and good afternoon, everyone. Thank you for joining us in this second time that we are doing this Q&A session at the end of the quarter. This is part of our effort to communicate better, to communicate more, more direct and more timely with our shareholders. Yeah, we hope that the topics that we have selected today are of interest for everybody. These are the topics that we would like to discuss. Together with me, as you can see, is Ole Thastrup, our CSO and Founder. The topics in the presentation are going to be related to the development of our commercial pipeline, which is a topic of interest for all our shareholders. Preliminary Q2 results compared to the goals that we have for the year. We would like to share some highlights about our participation at ESMO GI, some change in our commercial organization as well, and then a topic related to the regulatory framework and our transition to IVDR, and the importance of a notified body. These are the topics that we have selected for the presentation today. I will try to keep it short so that there is enough time for the Q&A session, because we think that's the most interesting part is that we address whatever our shareholders are willing us to talk about. I will start with this slide, which is related to our commercial pipeline. What you see here, and we have already shared that before, in quarterly reports, is, let's say, from the moment a hospital. For the moment a professional in a hospital learns about 2cureX for the first time, and about IndiTreat for the first time, to the moment when they would be routine users of IndiTreat, there are several steps that need to be followed. This is what we call the commercial pipeline. Okay? These steps are basically that first, typically, there is a first presentation, there is a first discussion. The clinicians have to confer among themselves. They confirm that, yes, they are interested in this topic. We have to start discussing the early access program. How are they going to get access to the samples in the first place? We sign or we make an early access agreement, what we call the IGNITE program. They start sending samples under this IGNITE program, and then at one point, we start a discussion of economic terms. Remember all the time that it is not the oncologists who are making the decisions about what they use or not use, it's their institutions. The oncologists can try to use something, they can ask their institution to buy a test, but it is not the final decision of the oncologist. There is an economic decision-makers and gatekeepers involved there. What I want to highlight here is we have, as of end of June, conversations in these five first steps of our pipeline. We have ongoing conversations with 201 hospitals in 23 countries in Europe and Middle East. This is an addition of 53 since January 1st. From January 1st until now, we have added to the pipeline 53 hospitals. Now, 201 hospitals. As I said, it's not just that we have listed the name of a hospital, we have ongoing conversations with them in different stages. 30 of these 201 are already in the IGNITE phase, so at the end of what you are seeing here. What I want to emphasize is that this is absolutely unique. There is no other company in the functional drug sensitivity space, none of our competitors is by far having anything similar. 201 ongoing conversations, a pipeline like this, has to be seen as a huge asset of the company, and we dedicate a lot of resources and effort to building this asset. In case some people are curious, the top 3 countries in terms of number of hospitals in the pipeline are Poland, Spain, and Germany. That's not surprising. These are the 3 largest countries in terms of population where we are present. What might be more interesting is, which are the 3 that have grown the most in these 6 months, in number of operations or number of ongoing conversations? These are Switzerland, Portugal, and then Finland and Germany with the same number. These are the countries that have been more successful, let's say, in adding new hospitals to the pipeline. Again, I think this is something that we are very proud of because this is exactly what we need for the future. We get a lot of questions about how is your sales process going? When do you expect to have sales? Et cetera, et cetera. The process has to be like this. I mean, each of these steps has to be followed. The more hospitals we have in this process, in this pipeline, and the more hospitals we are transitioning from one side to the other, the closer we will be to the endpoint, which is that hospitals are using IndiTreat as routine. The goals that we had for the year, you remember them, we had revenue goals, we had commercial rollout, and we had sample tested. These are the quantitative goals. We anticipate already, or I anticipate already there is no change to the communicated goals, so we are keeping all of them, still as our goals for the rest of the year. Starting with the revenue, where are we, in terms of revenue at the end of Q2? We have so far generated revenue about SEK 1.5 million. Okay? By now, in our original plan, we wanted to have SEK 2 million, so we are 25% below. Remember that our revenue comes from two sources: it comes from grants, and it comes from commercial sales. The grants revenue coming from the already known grants, IRES, Decider, Adapt is slightly below plan, but this is only due to shifts in the moment when we receive. We can only recognize the revenue when we have received the funds. There is a matter of timing of the payments, but the total amount for the year will be as planned. On top of that, remember that last quarter we announced that we had received, or we had been awarded, actually, 2 additional grants. These are incremental, and they have not generated any revenue in Q2. Actually, we expect the first impact to be in Q4. What you see here is the result of the existing grants, the previously existing grants. In terms of commercial sales, we have generated sales of SEK 65,000, which are basically sales of the sample collection sets that we are selling to our distributors. This is a lower level than we had originally planned. Many distributors still have inventories of the previous sample collection set. You might remember that we changed in the first quarter. Therefore, we expect this will take over, or this will take up, but for the time being, in commercial sales, we are below the plan. SEK 65,000 is a start that we didn't have in Q1. As said before, the goal for the year, which is 6 million SEK, we are keeping as such. In terms of number of samples, as you can see here, we have tested in Q2, we have tested 2.5 times the number of samples that we tested in Q1. Overall, we are in the accumulated at 64 samples tested. In the original plans, we wanted to be 125, so we are below plan. On the one side, and we have discussed this, hospitals take time to start sending samples, even under the IGNITE agreements. Remember, this is not a standard procedure. They have to collect a biopsy that is not standard, they have to send it to us, et cetera. There is a lot of alignment and multiple departments in the hospital that need to be aligned. This is explaining part of the delay that we have compared to the plan. The other part, which is also important, is We wanted to start in the first half of the year, 2 studies that would have contributed to the number of samples tested. These are not regulatory studies, these are not development studies. These are studies for the products that we already have in the market. It's a way of, let's say, fostering adoption. For reasons of mainly connected to our cost containment measures, you know that we have a certain runway that we are trying to preserve. We are tight in our cost consumption. We decided to shift the beginning of these studies to the second half. Part of the effect that you see here is also that. Anyway, we plan to start these studies in the second half, and we still maintain the goal of 500 samples for 2023 as originally planned. In terms of number of countries, you know that here we didn't want to grow a lot more countries compared to what we already have. We thought that we would have already one more in Q2. We haven't prioritized this. Our priority is that we have to continue pushing and supporting our distributors with activating the IGNITE sites. We are at 20, but we don't have any doubt that we will be at 25 at the end of the year. Our priority, we have mentioned that before, is adding Benelux, Italy, and France. These are our next priorities in this sense. Interestingly, we are already in dialogue with several hospitals in these countries. Although we don't have a distributor or a direct operation in these countries, we do have hospitals that we are talking to in the pipeline. We are talking to them directly without intermediaries. We have Some of them have even sent samples. We are receiving samples from countries where we don't have distribution active. Again, here we are keeping our goal for of 25 countries by the end of the year. I wanted to speak briefly about ESMO GI. You know, probably if you follow us, you know that in the couple of weeks ago, we had a booth. Main theme of the booth was what you see here, no more: The latest innovation in metastatic colorectal cancer treatment is not a drug. That's that was provocative, I would say, in a nice way, because when everybody thinks when oncologists think of innovation in treatment, they think of drugs. What we are telling them here is you can innovate in treatment, not by using new drugs, but actually by using them better, differently. We had similar traffic at the booth as we had last year, approximately 150 registered contacts, which is a lot. We saw clearly a qualitative difference in the maturity of the discussions. Last year there was a lot of first-timers, to the concept of functional drug sensitivity testing, people that we had to explain for the first time what this was about, et cetera. This year, we have seen that a lot of people already heard about this, already heard about IndiTreat, already have been in the conversations with us or with our distributors. The level of maturity that we had in the conversations was much, much higher. We had leads from 35 countries, just as anecdotes, U.S. to New Zealand and everything in between. Obviously, as of now, we are focusing in Europe and Middle East. From the bunch of countries that from our current territory, Israel, Portugal, Italy, U.K., and Benelux were especially active in terms of people stopping by the booth and engaging with us in conversations about IGNITE, how can we use this, et cetera. It's, it's also interesting anyway, and for us, the idea that we already have now a number of contacts of hospitals that are interested in the U.S., means that as soon as we are ready, from point of view of sample logistics, et cetera, as soon as we will be ready to initiate operations in the U.S., we are not starting from scratch, we are starting from conversations that we are already having. One of the things that we did in this conversation was asking our, our counterparts, okay, so you are a GI oncologist, so you are dealing with metastatic colorectal cancer. What about pancreatic cancer? Are you also treating cancer, pancreatic cancer patients, and would you be interested in an IndiTreat test? 85% of them responded positively and showed high interest in a pancreatic cancer test. This is important because, as we have already disclosed, our next step in terms of pipeline portfolio development, once we have finished with the colorectal cancer panel, is going to be entering pancreatic because it's a no-brainer. I mean, we are addressing exactly the same the same patient, the same customer population, customer segment. Therefore, it was very encouraging to engage already in discussions about pancreatic, which we could also trigger because we had a poster of pancreatic cancer presented together with our partner, UKE, from Eppendorf. Here, I think I want to use this quote from, Nature Reviews Clinical Oncology, which, was published a couple of weeks before the ESMO GI, because I think this reflects this degree of maturity that we have been talking about in the last, year and a half, in the sense that 5 years ago, 10 years ago, the concept of functional drug sensitivity testing based on three-dimensional cultures of the tumor was totally visionary. I mean, nobody was talking about this except Ole and a few more people in the world. Nowadays, it's totally mainstream, and if you read the quote, and allow me to read the quote: genomics-based precision medicine has revolutionized oncology, but also has inherent limitations. Functional precision oncology is emerging as a complementary approach that aims to bridge the gap between genotype and phenotype by modeling individual tumors in vitro. I mean, this could be a quote from our website or from our, or from our brochure, or from our commercial materials, but it is not. It is from Nature Reviews. I think this is showing this degree of maturity that we have been talking about and the preparedness of the market that we are expecting to capitalize. I want to speak also briefly, those of you who follow us in LinkedIn have seen it already, but we have added one more person to our team, Lennart Bønnelykke. I'm not sure the pronunciation is right, but excuse my Danish here. Lennart joined 2cureX as Commercial Director, and he will be responsible for our sales team in direct markets, Scandinavia, Germany, Iceland, but also, and with full dedication, managing the activities of our distributors in their territories. It's no secret that, I mean, we have great distributors, but these distributors have other products in their portfolios. We need to make a constant effort to keep IndiTreat and 2cureX on top of their priorities, on top of their activities. Lennart has more than 15 years experience doing exactly this, managing global distributor markets in companies like Dako, Sysmex, Sakura, Biocartis, and Veracyte. Prior to that, Lennart, by training, is a medical oncologist, and he started his career in Aalborg University Hospital, and he ended up in management positions in the Department of Pathology. This is very important. Lennart understands from the customer side also how things go. His main job, as I said, is going to be to supervise and support distributors and make sure that they deliver on the agreed commercial targets. This is something that until now was being done by Jesper Floyd Kristiansen, you know him. Jesper will now concentrate in opening of new markets and special partnership projects, and will leave this daily pressure, if you want, of the commercial operations with the distributors to run. Finally, I want to use this slide that you probably have seen also in the quarterly report or in the annual report, actually, if I remember correctly, which is related to our IVDR roadmap. You might remember that we have to transition from our products, which are currently CE marked under IVDD, need to be recertified under the new and much more stringent regulation, IVDR. We had this timeline, and one of the things in the timeline, a very important one, is that we had to engage with a notified body. Why is it a very important one? Because the shortage of notified bodies has been the bottleneck, and this is the main threat towards compliance with IVDR by most of the players in the IVD space. This MedTech Europe has estimated that up to 54% of the mid and small-sized companies might be at risk of not meeting the deadline of May 2025. The good news is, although the notified bodies are very selective before accepting a company as a customer, we have engaged with a notified body, and we have successfully passed their screening process. We expect that the final contract will be signed within quarter 3, and that's one quarter before we expected. This means that we can start working together with them earlier than expected. We think this is very good news. We were very satisfied with this because, as said, this has been the threat, the hidden threat for all companies is not being able to engage a notified body. With this, and I would like to finish the presentation and move to the Q&A. I think we have some questions already received, and then we will be receiving additional questions during the session. Thanks, and looking forward to the questions from the moderator. Perfect. Let's jump into the Q&A. Remember that the line is still open for questions. The first question is: If we look at other industries that are not comparable, many companies begin to close markets and focus on specific geographic areas, as operating in multiple markets and multiple countries is more expensive. Is this a risk or issue for 2cureX as well, as you're expecting to cover 25 countries end of this year, which seems like many different countries compared to the amount of revenue and tests you expect? Or is it important to cover many countries that early? I think that's a very insightful question. I think what we have to remember all the time is that our product is not a mainstream product, it's a disruptive product. We are creating a new category of products. This technology is not being used routinely. Therefore, because it's not mainstream, I mean, we are pitching and presenting to all oncologists, but in reality, we are targeting a very small percentage of the oncologists. That's the innovators and the early adopters, those that are willing to take the risk to do things before the others, before guidelines, before everything. This percentage of oncologists is not big, and therefore, if we would focus only in one country, that would be a problem, because finding these oncologists is not that straightforward. The more countries we have, the easier it is for us to get in touch with these early adopters and innovators. Also remember that until we are in mainstream reimbursement schemes, we are also addressing alternative payment methods, being patients paying out of pocket or charities or grants or whatever it is. Therefore, also here, it would be very risky for us if we would concentrate in just one country. What's good about our model with the distributors, I mentioned one problem with the distributors, of course, they have a lot of other products, so you have to keep pushing to get their attention. The advantage, obviously, is it is a very affordable model. We don't have to make any investment upfront there. We still think that, all things considered, going to several countries at the same time is the best strategy for 2cureX at this point. Thank you. The next question is: Have you experienced increased interest from existing and potentially enrolled in the treat hospitals after the positive trial results was published in Journal of Experimental & Clinical Cancer Research? Let me take that one. Yes, certainly, we have. It was great to see the TICC trial, as we call it. That was the first interventional trial where a drug sensitivity test is guiding treatment. As some of you may remember, the trial went very well. We surpassed the endpoint significantly. It just came out at the right time. Fernando presented the quote from the Nature article in May. We just came out before that. The timing was just about right. The ESMO meeting showed that people are now more educated about the drug sensitivity test. Having a new paper out with very positive results have certainly steered a lot of interest. Thank you. Here we have a few questions about the cash flows. One of them is: Could you dive deeper in the plan to reach positive cash flow? It seems to me that equity funds will come to an end within 12, 18 months. What is the plan? Sell rights, new owner, new shares, loans? I think this is the main reason why the stock share has been fallen during the last year. To me, except for increasing sales, the most important issue right now is how to fund the company further and give the stock market or owners a clear road forward. Yeah, we probably agree that there might be a relationship between the low trading volume and the expectation from shareholders to understand the future funding pathway of the company. We said already in our Q1 report that we are constantly, and literally constantly, working on multiple fronts to improve our cash position. We want to improve our cash position not only to extend our runway, but also to accelerate our development plans. The company has been around for many years, waiting for this moment of maturity of the market, and we cannot be shy now in what we need to do. We are constantly exploring all options, all funding instruments, dilutive, non-dilutive, hybrids. In Q1, for example, we were awarded already 2 important grants, we have mentioned already. We have more applications for grants outstanding, some of them significant. The only thing we can say at this point is that in this exploratory work, we are very encouraged by the many options that are available for a company like 2cureX, which is very attractive, considering the market opportunity that we are addressing and the readiness and maturity of the company. When we are seen from the outside, we are analyzed from the outside, everything that we have built in the last years is seen as highly positive and attractive. It's also true that, yes, there are many, many options available for us, but we are in a very turbulent environment, and the different courses of action have to be very carefully assessed in order to preserve the interest of the shareholders and the development possibilities of the company. The only thing I can say at this point is that as soon as the management and the board have a specific proposal on this topic, it will be communicated. In the meantime, the only thing what we can do is we will continue to control expenses as tight as we can and make the most efficient use of our resources. I think at this point, there is not more that I can say on this topic. Thank you. The next question is about tests through IGNITE. How many tests done in Q2? How many paid full price? How many tests through other ways than IndiTreat during Q2? Forecast for Q3, Q4, and 2024, 2025. How many full price tests is forecasted for the mentioned periods? How many tests do you expect to need to be taken in guidelines? When can this occur? Okay, there was a number of questions. Let me first say that Fernando just presented the forecasted numbers for the remaining part of 2023, and also the actual numbers here in Q2. We do not in our when we publish our results, we do not sort of distinguish how many were of the sort of were paid and non-paid. We focus on the number of tests and the revenue. There, we are certainly beyond 2.5 times beyond Q1, so we are definitely on the right track. Now, we have not presented any forecasted numbers for 2024 or 2025. We think that would be premature to do that. We will, in Q3 of this year, present the forecast for 2024. We will have to wait for the 2025 till next year. This question about how many tests do we expect that are needed for the IndiTreat to pick up in guidelines? That's a very interesting question, because we actually see the route to mainstream use as 2 parallel tracks. There's one that is related to have the IndiTreat into clinical practice. We want to establish a change in clinical practice. The other track is reimbursement. Clinical practice change, that is something that happens with some very fast, those we call early adopters. There are sort of the main adopters and late adopters. As we sort of pass through this group of different adopters, reimbursement starts to kick in, and the reimbursement will be different from country to country. When all this is the sort of being implemented, it will sneak into guidelines. Having your test in guidelines is not the same as having reimbursement. And certainly not the same as having it in clinical practice. We are pushing the clinical practice, we are working on the reimbursement, and then the guidelines, the entry into guidelines will happen, and that will happen globally. I mean, the guidelines are controlled by two major scientific societies: ESMO, that Fernando just talked about, in Europe, and ASCO in the U.S. We are pushing these tracks until we get the mainstream use and then into guidelines. Thank you. The next question is: other companies have started selling their products to private individuals. Have 2cureX thought about the same thing? The patients certainly have a great need. Absolutely. I mean, the patient have a great need for this test, that's absolutely true. What we have to realize is that our test is actually not an isolated product. Our test is kind of in between or embedded in a medical process, if you want. Before our test, there has to be a biopsy, because the sample that we are using as a basis for the test is a biopsy, and after the test, there is a treatment decision, and there is a treatment execution that comes as a consequence of the test. Therefore, we cannot work isolated from the pre or from the pre and post IndiTreat process, so to say. In this sense, we cannot sell then this isolated something isolated directly to the patient. We have to sell this to the institution that is treating the patient. How the institution relates to the patient is different, depending on whether it's a private institution, a public institution, whether it is different countries, et cetera, et cetera. There might be opportunities for the patient to pay out of pocket, but when we say patient paying out of pocket, the patient is not going to pay out of pocket to 2cureX. Patient is going to pay out of pocket to the treating institution, and our relationship is always with the treating institution. Since you mentioned the patients, I obviously, as I said, we cannot sell to them directly. In fact, when we receive a call or an email from a patient or a patient family, which happens sometimes, patient relative, first thing we have to do is refer them to an oncologist. Say: w e are happy to help you, but we need an oncologist to make the requisition of the test. But what we are starting to do, and we will emphasize and continue to with more intensity going forward, is collaborate with patient advocacy groups. Okay? Because, yeah, yes, it's true that we cannot sell directly to patients, but we can help with the patient education, we can help with the patient awareness, we can help with all these things. Thank you. The next question is: can you tell us more about the IndiTreat test lab box? Has it been decided with a specific hospital that will start testing it now in Q3, Q4? Still waiting for updates to the box before starting the test. I think that the shareholder probably refers to our automation project, where we have been out saying that we want to decentralize testing. We want to allow hospitals to conduct the IndiTreat test themselves. We think this will provide a number of benefits. Not only can we go to territories outside Europe, but we can also access hospitals that are not that excited of sending out material. That project is certainly going very fast at the moment. We have a collaboration with Hahn-Schickard in Freiburg, and we have an instrument sitting in Copenhagen that is being tested and being updated. What we have mentioned to the market is that there will be an IndiTreat prototype to be tested at a hospital by the end of 2023. That still holds. We are pretty sure that that will happen. Such a instrument will have to be CE marked, and that takes time. To get it out in the hospitals are very important for us because we will get a lot of sort of test data back, that are important to finalize the product. We cannot say exactly which hospitals it will be, we are not allowed to. I can say that we have several hospital opportunities that we are looking at the moment. Thank you. The next shareholder asks: From 2022 to now, the share has fallen by approximately 80%. What reasons do we investors still have to believe in 2cureX and keep investing, and have any idea who it is that is selling, large or small investors? Yes. I think the reason for investing is, and should always be, that there is a market opportunity that is huge. We are addressing a market that is going to become a more than EUR 1 billion per year market. We are the company that is in the best position to lead this emerging market. In the last three years, we have taken I mean, the company developed the technology. The company had IP-protected technology. What we have done in the last three years is everything related to market readiness. We have CE mark. We have developed an CE mark, three different products. We have built a distributor network. We have built this pipeline that I was alluding at the beginning, more than 200 hospitals only in Europe and Middle East. We have been ISO 13485 certified. We are in track for the transition from IVDD to IVDR. We have a fantastic team, experienced and motivated. To me, these are the reasons for investing in a company. There is a market opportunity, and there is a company that is ready to address this market opportunity and to capture this market opportunity. That's all I can say at this point. Maybe I could add, Fernando, that there is this question of whether we have an idea of who it is that is selling. We are obviously aware of the issue with the share price, and therefore, are also looking into who are coming in, who are going out. There, I would actually point your attention to our website and look at the owner list. We just updated that two days ago, then we got the newest owner list for Q2 from Euroclear, and that's the 10 biggest owners. All of those, none of them have been selling. Two of them have been buying. I cannot say who that are selling, but I can say that it's not the major shareholders. They are increasing their stake. That's the closest I can get. Thank you. The next question is, are your sales targets for 2023 intact despite the weak start to the year? Yeah, I think I covered this in the presentation. I said our targets are unchanged. The next question is: Do you understand why the stock has collapsed completely? It would be nice to hear if you are connected or disconnected to the market and your shareholders or not. A few of your own words and thoughts on why it has gone this bad would be very interesting. Thanks. I mean, at the end, the share price is the consequence of many individual positions. It's not our place to judge these individual positions. If somebody decides to sell, somebody decides to buy at certain prices, this is not for us to judge. Yes, one can have hypotheses about why or why not. I think one of the questions was hypothesizing. People are maybe waiting to understand what is the pathway to funding. Maybe there are environmental reasons as well. There is the macroeconomic reasons. There are many reasons, it is certainly not our place to judge what decisions each investor makes. I will only emphasize once again, what we have been saying from the beginning, which is we think that the best we can do for the company and for the value of the shareholders, is to keep working on building the value of the company in terms of the fundamentals of the company. I just mentioned everything that we have in place. If you look around, if you compare us to any of our competitors, to any of the companies that is out there, you will see that we are in a position where nobody else is at this moment. We think the best we can do is to continue focusing on this and expect that finally, this will be reflected in the share price when the conditions are right. Thank you. The next shareholder asks: Did you manage to hire the new lab technician you were looking for on LinkedIn? Is this hiring a precaution for forecasted potential volumes later, or are you already feeling the heat in the lab in terms of capacity and need to expand ASAP? I can confirm that we have hired a new member of our technical staff. We actually signed his contract here just a few days ago. What's the reason? Well, obviously, we have told you that we have increased the number of samples from Q1 to Q2, about 2.5 times. That does put pressure on our lab activities. Further, we have a number of other activities that is not directly related to these. I mean, we have also activities in pancreas and ovarian, and you should also be aware that we are moving to what's IVDR. Part of the IVDR process, is that we need to do a lot of stability studies. We need to evaluate different components of the test that needs to go in to the technical file. All this require additional staff. It is welcomed that we get more staff. We do have capacity to increase the IGNITE and IndiTreat samples as we have forecasted. Thank you. The next question is: how many tests have been executed until end of June? Is it in line with the communicated sales plan of approximately 100 tests? If not, what is the reasons for the deviation? Yeah, I would think that this has already been covered as well in the presentation. Yeah. Thank you. The last question asked before the event: are you planning to start selling something anytime soon? Well, I mean, strictly speaking, we have started selling. We have been selling these kits to our channel, to our distributors. I think I explained in the presentation, the pipeline, I explained in the presentation, what are the steps. There is no way you can skip this. There is no way that you can find somebody who is willing to pay immediately without even trying the test. This is a process that needs to be followed. The way we are addressing this is, we are filling this pipeline, and we are pushing this pipeline forward. I'm sure that with this I mean, we are seeing on a quarterly basis, we are seeing the maturation. We are seeing how hospitals are transitioning from one step to the other. Eventually, sooner than later, we will have the first, hospitals in the end of the process, which is using IndiTreat in routine and paying. Great. Thank you. We have one question asked live. I think you had some great progress the past years. Great work. Just a bit more personal question: how did the negative share and some dissatisfied shareholders affect your commitment and energy at 2cureX? Thanks again for your fantastic work. Okay, let me formulate it. That's a different, difficult question. I think, first, our commitment, as you can imagine, is as high as it has ever been, and this is not declining. I mean, although the share price, it's true, the development of the share price is not what we would like to see and not what we would have expected, but the development of the company as such is as I have described, is very positive. The people who are involved including ourselves, Ole and I, who are involved in conversations with customers, in conversations with distributors, in et cetera, et cetera, we are seeing the progress, and this keeps, of course, us highly motivated. In terms of commitment, in terms of motivation, I would say, nothing has changed. We understand the frustration. Not only we understand, we share the frustration with the share price. I said, I mean, we have to respect that there are certain dynamics, and all we can do is basically, what we have already discussed. Ole, maybe you have a different perspective here. No, I do certainly not have a different perspective, and the only thing I can add is that you can actually see that the major shareholders, of which some are in the management, have not sold a single share but have acquired. Further, we have not lost staff members. Actually, the opposite, we have been able to attract people. I would say the motivation is there, but I can share, Fernando, there is some frustration, but we are working ourselves out of it, and not the least with the stuff we see that works. I mean, just seeing f or me, I would say that I've been in this for so many years, I almost get tears in my eyes when I see a box with the 2cureX logo sitting in a department at the hospitals. That gives you energy. No, the motivation is certainly there. Thank you. That was all for the questions. Before we end this webcast, I will hand over the mic to 2cureX for your final remarks. Yes. Just thanking the people who have joined us and probably the people who will listen to this afterwards. Thank everybody for the interest in 2cureX. Thank everybody for the trust in 2cureX, despite everything. I want to once again emphasize the opportunity and the readiness of the company are there, and with this, it will, at the end, it will move forward as we all want to move forward. That's what should guide us. Thanks for joining. Thanks for your time. We have extended a little bit more, but I think that was a very interesting Q&A session. We hope we addressed the questions. We aim to continue doing these quarterly meetings, so next one will be sometime the beginning of October. That's it for now. Thanks a lot, and have a good evening. Thank you.